 Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
| Descriptor ID |
D014409
|
| MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D23.529.374.500.800 D23.529.374.750.626
|
| Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- TNFalpha
- TNF-alpha
- Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Cachectin
- TNF Superfamily, Member 2
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 3 | 3 | | 1995 | 3 | 0 | 3 | | 1996 | 0 | 2 | 2 | | 1997 | 1 | 1 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 1 | 2 | 3 | | 2001 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 2 | 3 | | 2005 | 6 | 2 | 8 | | 2006 | 6 | 2 | 8 | | 2007 | 1 | 3 | 4 | | 2008 | 2 | 6 | 8 | | 2009 | 3 | 4 | 7 | | 2010 | 4 | 8 | 12 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 3 | 5 | | 2013 | 1 | 5 | 6 | | 2014 | 5 | 5 | 10 | | 2015 | 1 | 4 | 5 | | 2016 | 3 | 5 | 8 | | 2017 | 4 | 4 | 8 | | 2018 | 2 | 3 | 5 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Haberman Y, Karns R, Dexheimer PJ, Schirmer M, Somekh J, Jurickova I, Braun T, Novak E, Bauman L, Collins MH, Mo A, Rosen MJ, Bonkowski E, Gotman N, Marquis A, Nistel M, Rufo PA, Baker SS, Sauer CG, Markowitz J, Pfefferkorn MD, Rosh JR, Boyle BM, Mack DR, Baldassano RN, Shah S, Leleiko NS, Heyman MB, Grifiths AM, Patel AS, Noe JD, Aronow BJ, Kugathasan S, Walters TD, Gibson G, Thomas SD, Mollen K, Shen-Orr S, Huttenhower C, Xavier RJ, Hyams JS, Denson LA. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019 01 03; 10(1):38.
-
Ricciuto A, Dhaliwal J, Walters TD, Griffiths AM, Church PC. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis. J Crohns Colitis. 2018 Nov 15; 12(11):1302-1315.
-
Bortoluzzi A, Valesini G, D'Angelo S, Frediani B, Bazzichi L, Afeltra A, Paolazzi G, Doria A, Meroni PL, Govoni M. Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus. Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii32-vii41.
-
Church PC, Hyams J, Ruemmele F, de Ridder L, Turner D, Griffiths AM. The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World. Can J Gastroenterol Hepatol. 2018; 2018:3190548.
-
Okihiro A, Hasija R, Fung L, Cameron B, Feldman BM, Laxer R, Schneider R, Silverman E, Spiegel L, Yeung RSM, Tse SML. Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatr Rheumatol Online J. 2018 Mar 14; 16(1):17.
-
Leclercq M, Le Besnerais M, Langlois V, Girszyn N, Benhamou Y, Ngo C, Levesque H, Muraine M, Gueudry J. Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review. Clin Rheumatol. 2018 Mar; 37(3):849-853.
-
Ricciuto A, Kamath BM, Walters TD, Frost K, Carman N, Church PC, Ling SC, Griffiths AM. New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children. J Pediatr. 2018 03; 194:128-135.e1.
-
Wang W, Fujii H, Kim HJ, Hermans K, Usenko T, Xie S, Luo ZJ, Ma J, Celso CL, Dick JE, Schroeder T, Krueger J, Wall D, Egeler RM, Zandstra PW. Enhanced human hematopoietic stem and progenitor cell engraftment by blocking donor T cell-mediated TNFa signaling. Sci Transl Med. 2017 Dec 20; 9(421).
-
Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Philipp S, Szalai Z, Vleugels RA, Holland K, Murphy R, Baselga E, Cordoro K, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Paller AS. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. JAMA Dermatol. 2017 11 01; 153(11):1147-1157.
-
Raffeiner B, Grisan E, Botsios C, Stramare R, Rizzo G, Bernardi L, Punzi L, Ometto F, Doria A. Grade and location of power Doppler are predictive of damage progression in rheumatoid arthritis patients in clinical remission by anti-tumour necrosis factor a. Rheumatology (Oxford). 2017 08 01; 56(8):1320-1325.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|